PROTACs: Novel tools for improving immunotherapy in cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Posttranslational modifications (PTMs) regulate protein levels.
• Proteolysis targeting chimeras (PROTACs) induce targeted protein degradation.
• PROTACs offer a novel approach to target previously undruggable proteins.

Purpose of the Study:

• To review the role of PROTACs in cancer immunotherapy.
• To elucidate how PROTACs regulate specific molecules to enhance immunotherapy.
• To highlight the therapeutic potential of PROTACs in cancer treatment.

Main Methods:

• Literature review of PROTAC technology and its application in cancer immunotherapy.
• Analysis of PROTACs targeting specific proteins like HDAC6, IDO1, EGFR, and PD-L1.
• Examination of PROTACs' mechanism in regulating protein expression for therapeutic benefit.

Main Results:

• PROTACs effectively induce ubiquitination and degradation of target proteins.
• Targeting molecules such as HDAC6, IDO1, EGFR, FoxM1, PD-L1, SHP2, HPK1, BCL-xL, BET proteins, NAMPT, and COX-1/2 with PROTACs can modulate cancer immunotherapy.
• PROTACs demonstrate potential in improving immunotherapy outcomes in cancer patients.

Conclusions:

• PROTACs represent a promising therapeutic strategy for cancer immunotherapy.
• Targeted protein degradation via PROTACs can overcome resistance mechanisms and enhance treatment efficacy.
• Further research into PROTACs may unlock new avenues for cancer treatment.